Review article · 2025 · Open access
Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies
Infection and Drug Resistance, Volume 18, 715–729 · Published 1 February 2025 · DOI 10.2147/idr.s493670
In brief
“Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies” is a 2025 review article by Yuqing Cui and 2 co-authors, published in Infection and Drug Resistance. OpenAlex counts 14 citations as of 18 November 2026, which puts it in the top 5% of works published in 2025 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Infection and Drug Resistance.
- Citations
- 14
- Most cited in
- 2026 (11)
- Field-weighted impact
- 1.40
- References
- 76
- Authors
- 3
Abstract
Purpose: Since the publication of the 2011 Infectious Diseases Society of America (IDSA) guidelines for empirical treatment of febrile neutropenia (FN), there have been significant shifts in pathogen profiles and emerging challenges in treatment. These include increased prevalence of multidrug-resistant (MDR) bacteria and changes in the distribution of Gram-negative or Gram-positive bacteria (GPB). The study aims to update and optimize empirical treatment strategies for hematological malignancy (HM) patients, a population particularly vulnerable to these evolving threats. Methods: A literature review was conducted on studies published between January 2010 and December 2023 regarding empirical treatment of FN in HM patients, focusing on pathogen characteristics, treatment regimens, and duration of therapy. Results: Approximately one-third of HM patients with FN experience fever of unknown origin (FUO), while 40– 50% have clinically documented infections (CDI), and 10– 30% present with microbiologically documented infections (MDI), with a predominance of Gram-negative bacteria (GNB). Factors such as prolonged neutropenia, prior broad-spectrum antibiotic use, and previous infections with drug-resistant bacteria are associated with MDR infections. Cefepime, piperacillin/tazobactam (PTZ), and carbapenem are viable empirical treatments for high-risk HM patients, though cefepime monotherapy’s advantage remains uncertain. In cases of pneumonia, shock, or suspected carbapenem-resistant infections, combination therapy, tigecycline, and newer antibiotics like ceftazidime/avibactam (CAZ/AVI) are often used. Empirical broad-spectrum antibiotics can be safely discontinued in FUO patients after 48 hours of clinical stability and apyrexia. Conclusion: Proper selection of empirical antibiotics and determining optimal treatment duration are essential for reducing antibiotic resistance and improving outcomes in HM patients with FN. These findings underscore the need for updated clinical guidelines that address evolving pathogen profiles and the growing challenge of MDR infections. Summary: Infection-related complications remain a leading cause of mortality in HM patients, often limiting the implementation of chemotherapy. Early and appropriate empirical therapy significantly improves outcomes in FN, reducing hospital stays and healthcare costs. Effective treatment strategies require careful evaluation of local microbial epidemiology, risk factors for drug resistance, and predictors of poor prognosis. For high-risk FN patients, first-line antibiotic options include cefepime, PTZ, and carbapenems. In cases of pneumonia, septic shock, or suspected carbapenem-resistant infections, combination therapies with antipseudomonal β-lactams, aminoglycosides, or novel agents like CAZ/AVI are recommended. In patients with FUO, discontinuing broad-spectrum antibiotics may be considered 48 hours after defervescence in clinically stable patients, though premature cessation should be avoided for those with persistent fever. Ongoing monitoring and reassessment of the patient’s condition are crucial to minimizing the risks of treatment failure. Timely, evidence-based empirical therapy remains critical for improving outcomes in FN, and continued advancements…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Cui, Y., Liu, X., & Feng, S. (2025). Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies. Infection and Drug Resistance, Volume 18, 715–729. https://doi.org/10.2147/idr.s493670
MLA 9
Cui, Yuqing, et al. “Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies.” Infection and Drug Resistance, vol. Volume 18, 2025, pp. 715–729. https://doi.org/10.2147/idr.s493670.
Chicago
Cui, Yuqing, Xin Liu, and Sizhou Feng. 2025. “Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies.” Infection and Drug Resistance Volume 18: 715–729. https://doi.org/10.2147/idr.s493670.
Harvard
Cui, Y., Liu, X. and Feng, S. (2025) ‘Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies’, Infection and Drug Resistance, Volume 18, pp. 715–729. doi:10.2147/idr.s493670.
IEEE
Y. Cui, X. Liu, and S. Feng, “Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies,” Infection and Drug Resistance, vol. Volume 18, pp. 715–729, 2025, doi: 10.2147/idr.s493670.
BibTeX
@article{cui2025clinical,
title = {{Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies}},
author = {Cui, Yuqing and Liu, Xin and Feng, Sizhou},
journal = {Infection and Drug Resistance},
year = {2025},
volume = {Volume 18},
pages = {715--729},
doi = {10.2147/idr.s493670},
url = {https://doi.org/10.2147/idr.s493670}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- febrile neutropenia
- hematologic malignancies
- empirical antimicrobial therapy
- multidrug-resistant bacteria
- Gram-negative bacteria
- Gram-positive bacteria
- cefepime
- piperacillin-tazobactam
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Cui, Y., Liu, X., & Feng, S. (2025). Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies. Infection and Drug Resistance, Volume 18, 715–729. https://doi.org/10.2147/idr.s493670
How many times has this paper been cited?
14 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Infection and Drug Resistance: sign in and open the PDF from this page.
Who wrote this paper?
Yuqing Cui, Xin Liu, Sizhou Feng.
What is the DOI of this paper?
10.2147/idr.s493670, permanently at https://doi.org/10.2147/idr.s493670. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.